Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells

Lili Yang · 2025-08-12

22Citations
1Influential
Ovarian cancer (OC) poses a significant challenge for conventional chimeric antigen receptor-engineered T (CAR-T) cell therapy, due to frequent recurrence linked to tumor heterogeneity, platinum resistance, immune evasion, and an immunosuppressive tumor microenvironment (TME). Here, we analyze primary OC patient samples and identify a unique opportunity for allogeneic CAR-NKT ( Compared to conventional CAR-T cells, These findings underscore the unique efficacy and safety advantages, as well as the off-the-shelf potential of Major funding was provided by the California Institute for Regenerative Medicine (CIRM).
Links
DOIPubMed
Journal
Med
TL;DR

Compared to conventional CAR-T cells, AlloCAR-NKT cells demonstrate superior anti-OC efficacy, showcasing multiple OC-targeting mechanisms, focused tumor homing, and pronounced TME modulation.

AI-generated by Semantic Scholar

Institutions
University Of California Los Angeles
Authors
Lili Yang
Funding
Congressionally Directed Medical Research Programs Grant CA200456Exploring super charged NK cells as a novel cell-based immune therapy in targeting platinum resistant ovarian cancersBCCMA: Overcoming chemoresistance in ovarian cancer: Targeting Unique Vulnerabilities in Neuroendocrine-like Ovarian Cancer CellsUS Department of Defense FundingCalifornia Institute for Regenerative Medicine FundingCalifornia Institute of Regenerative Medicine Grant TRAN1-16050California Institute of Regenerative Medicine Grant DISC2-13015California Institute of Regenerative Medicine Grant DISC2-11157California Institute of Regenerative Medicine Grant TRAN1-12250University of California, Los Angeles FundingHarvard University Center for AIDS Research Funding

U.S. Department of Veterans Affairs

I01BX006411

U.S. Department of Veterans Affairs

I01BX006019